We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA批准durvalumab联合BCG用于高风险NMIBC。POTOMAC数据：风险降低32%。分析疗效、毒性及BCG短缺的影响。了解更多。
